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and diffuse long lesion group (more than 30 mm, n=127).
Results: Baseline clinical characteristics & procedure details were similar between the
two groups, except pts with diffuse long lesion were more smokers (59.1% vs. 46.3
%, p: 0.044). In long lesion group; use of retrograde approach, numbers of wires,
microcatheter, amount of dye and total fluoroscopy time, were higher. Except for
perforation, procedure related complications were similar between the two groups. At
one year, diffuse long lesion group showed worse clinical outcomes including higher
incidence of target lesions revascularization (TLR), target vessel revascularization
(TVR) and TLR-major adverse cardiac events (MACE, Table).
Conclusion: Diffuse long CTO lesions needed more complex procedure techniques
and devices. Further, those were associated with worse clinical outcomes at one year
follow up as compared with shorter CTO lesions.
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Background: Stent fracture is related to restenosis after drug-eluting stent (DES)
implantation. As percutaneous coronary intervention (PCI) cases for complex lesions
increase, those for stent fracture-related restenosis could also increase. However, the
optimal PCI strategy for such restenosis remains unclear. We evaluated the results of
PCI with plain old balloon angioplasty (POBA), DES, and drug-eluting balloon (DEB,
SeQuent Please) for restenosis with stent fracture after sirolimus-eluting stent (SES)
implantation.
Methods: From November 2002 to October 2010, 5334 patients with 6299 lesions
underwent SES implantation successfully. Of these lesions, 5298 were angiographically
followed after 6 to 8 months (midterm f/u) and 3981 were followed at 12 months after
midterm f/u (late f/u). Stent fracture occurred at 294 lesions (stent fracture rate, 5.5%)
and stent fracture with restenosis occurred at 123 lesions. Of these 123 lesions, target
lesion revascularization (TLR) by PCI with POBA, DES, or DEB was performed on
80 lesions.
Results: Data are shown in the table. At midterm f/u, the rates of restenosis and TLR
after restenting with DES were significantly lower than those after POBA. At late f/u,
there was no significant difference between POBA and DES. Late f/u was not
performed on the DEB cases.
Conclusion: Restenting with DES could be an acceptable treatment for restenosis with
stent fracture after SES implantation.
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Background: The number of PCI has been increasing during the last years in Europe.
Little is known about the characteristics of interventional treatment of in-stent-re-
stenosis (ISR) in clinical practice in Europe.
Methods: Between 2005 and 2008, 47,407 consecutive patients undergoing PCI were
enrolled into the PCI-Registry of the Euro Heart Survey Programme to document
patient characteristics, PCI details and hospital complications in different PCI
indications. We examined the differences between treatment of ISR versus de novo-
lesions in patients undergoing PCI for ACCS in clinical practice.
Results: A total of 14,011 patients underwent PCI for ACS, in 789 (5.6%) the treated
culprit lesion was an ISR. Patients with ISR more often were male; more often had
diabetes, prior MI and CABG than patients undergoing PCI in de-novo lesions. No
differences were found in the use of anti-thrombotic drugs despite a more frequent use
of GP IIb/IIIa receptor blockers even in patients with de-novo lesions rather than in
ISR. In ISR, 70.1% of patients did receive a stent, of which 64.6% were DES. The rate
of stenting in de-novo lesions was 94.8%, with a relative proportion of 38.0% of DES.
No differences were observed in hospital outcome.
Conclusion: The culprit lesion in consecutive patients undergoing PCI for ACS in
clinical practice in Europe was ISR in 5.6%. Patients with ACS treated for ISR less
often received new stents, of which only two third were DES. No differences were
found in hospital clinical outcome between patients with ISR or de-novo- stenosis in
ACS in clinical practice in Europe.
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Background: As Drug-eluting stents (DES) significantly reduce the risk of in-stent
restenosis (ISR), it has become common practice to perform PCI with DES for
unprotected distal left main (UDLM) stenosis. However, there is little available data
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regarding the optimal revascularization strategy in patients with DES-ISR of the
UDLM.
Methods: All consecutive patients with UDLM DES-ISR between March 2002 and
December 2008, were included in this retrospective analysis. The primary end-point
of the study was a composite of all cause death, myocardial infarction (MI) and target
lesion revascularization (TLR) within 2 years, and defined as major adverse
cardiovascular events (MACE).
Results: During the study period, 457 consecutive patients with UDLM disease
underwent DES implantation. DES-ISR of UDLM occurred in 92 (16.7%) patients.
Among the DES-ISR patients with UDLM, 8 (8.7%) underwent CABG, and 84
(91.3%) underwent PCI. Among the latter, 43 (50.6%) patients underwent PCI with
POBA and 42 (49.4%) underwent PCI with DES. MACE at 2-years occured in 33
patients (33%); 1 (12.5%) in the CABG group and 32 (37.8%) in the PCI group. In the
PCI group, the incidence of restenosis was higher following PCI with POBA than with
DES (48.9% vs.21.3%, p=0.008). On multivariable analysis, independent predictors
of repeat TLR were POBA {OR 3.52, 95% CI 1.28-9.66; p=0.015} and CKD {OR
3.81, 95% CI 1.02-14.31; p=0.047}. The original use of a 2-stent strategy at the distal
bifurcation was associated with significantly higher repeat TLR at restenosis lesions
of the circumflex ostium than was the use of a 1-stent strategy (52.0% vs. 14.3%,
p=0.038).
Conclusion: Restenosis of the UDLM should be treated with DES rather than POBA.
Although an initial 2-stent strategy increases the risk of recurrent restenosis at the LCX
ostium, this finding had little prognostic impact.
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Background: As drug-eluting stents (DESs) are being used in increasingly complicated
settings, DES restenosis is no longer an uncommon phenomenon, and its optimal
treatment is not known. The aim of this study was to compare the efficacy of paclitaxel-
eluting balloon (PEB) with repeat sirolimus-eluting stent (SES) implantation for the
treatment of SES restenosis.
Methods: From June 2004 to December 2010, 221 consecutive patients with 245
lesions after revascularization for SES restenosis were enrolled. Follow-up angiogram
was obtained 6 to 8 months after procedure. All of the initial SES were implanted in
de novo lesions. We compared characteristics of patients and lesions between the two
groups (PEB for SES restenosis: PEB group, n=131, repeat SES implantation for SES
restenosis: SES group, n=114).
Results: No significant differences were observed in clinical characteristics between
the two groups. Reference diameter (RD) and minimal lumen diameter (MLD) were
similar between the two groups (RD: 2.83 +/- 0.42 mm vs 2.91 +/- 0.48 mm, p=0.2,
MLD: 0.85 +/- 0.51 mm vs 0.91 +/- 0.52 mm, p=0.4). Lesion length was longer in the
DEB group (15.5 +/- 9.0 mm vs 13.3 +/- 6.9 mm, p=0.033). Acute gain was larger in
the SES group (1.20 +/- 0.62 mm vs 1.71 +/- 0.63mm, p<0.0001). Follow-up rate was
91% (223/245 lesions). The incidence of recurrent restenosis was 19.1% in the DEB
group and 24.1% in the SES group (p=0.4). DEB group led to a significant reduction
in 6-8 month late lumen loss (0.27 +/- 0.68 mm vs 0.63 +/- 0.74 mm, p=0.0002) and
in target lesion revascularization (13.0% vs 23.2%, p=0.049) compared to SES group.
Conclusion: In patients with SES restenosis, PEB provided much better angiographic
outcomes than repeat SES implantation.
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Background: Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel has been
proven to be effective to prevent acute thrombotic complications after coronary
stenting. Current guidelines recommend 300 mg the day before PCI or 600 mg
immediately before PCI and 4 weeks of DAPT for all patients treated with bare-metal
stents and a year of DAPT for patients treated with drug-eluting stents. The drug-eluting
balloon (DEB) studies support the use of paclitaxel-eluting balloons for the treatment
of in-stent restenosis, of small coronary arteries and bifurcations lesions. We analyzed
and compared the safety, focused on the rates of acute thrombosis after DEB in 8
current DEB studies with the outcome in a clinical setting.
Methods: A retrospective review was done of 191 consecutive patients who underwent
percutaneous coronary intervention procedure with the paclitaxel eluting balloon
SeQuent™ Please at a high-volume Heart Center in Potsdam from September 2009 to
February 2011. DEB were used for the treatment of in-stent restenosis, small coronary
arteries, bifurcations lesions, de-novo lesions or other indications. The primary
evaluation was acute coronary thrombosis. All patients were pretreated with aspirin
and clopidogrel, which was continued for 4 weeks.
Results: During hospital stay none of the 191 patients (0%) had suffered from acute
coronary thrombosis in the clinical setting. In conclusion no differences in the rates of
coronary thrombosis between the different indications for DEB were found. Moreover,
none of the patients treated with the DEB only strategy had suffered from acute
thrombosis. The rate of acute thrombosis after DEB in the clinical setting is comparable
to the results in the available DEB studies.
Conclusion: The use of DEB in routine daily practice does not appear to be associated
with a higher rate of acute thrombosis.
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Background: Even DES era there are some situations associated with a high risk of
restenosis and/or stent thrombosis. We wished to assess the efficacy of a new drug-
eluting balloon (DEB) in the treatment of these situations.
Methods: 249 patients were included in this prospective multicenter (10 Spanish
centers) registry using a new DEB (3.0μg/m2 balloon surface area) in the following
situations: in-stent restenosis (ISR) (49% DES): 126; de novo lesions in small vessels
(SMV) (≤2.5mm): 104 (42% bifurcation lesions); and in patients with a
contraindication to dual anti-platelet therapy (DAT): 19. The DEB was inflated for a
minimum of 60 seconds. Dual antiplatelet therapy was recommended for at least 1
month. The only exclusion criteria were acute STEMI and cardiogenic shock.
Results: In the following table are presented the main characteristics of this population
as well as 1-year clinical outcomes (median of 12 (6-13) months). Angiographic follow-
up was completed as follow: ISR (34 patients (79.1% of follow-up completed, 6.5 ±
2.1 months) and SMV (51 patients (84% of follow-up completed, of 7.5 ± 2.9 months).
It is important to note that 6 months angiogrpahic late loss was similar in both groups
(ISR 0.31mm and SMV 0.34mm).
In the table are presented the main characteristics of the population as well as 1-year
clinical outcomes (median of 12 (6-13) months).
Conclusion: In this un-selected population at high risk of restenosis and/or stent
thrombosis the use of this new DEB, provides excellent 1-year outcomes with high
efficacy (late loss 0.31-0.34mm) and safety (stent thrombosis 0.8-1%) despite a short
duration of dual anti-platelet therapy.
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